Data from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization Article Swipe
Rubén Niesvizky
,
Tomer M. Mark
,
Maureen Ward
,
David Jayabalan
,
Roger Pearse
,
Megan Manco
,
Jessica Stern
,
Paul J. Christos
,
Lena Mathews
,
Tsiporah B. Shore
,
Faiza Zafar
,
Karen Pekle
,
Zhaoying Xiang
,
S. Ely
,
Donna Skerret
,
Selina Chen‐Kiang
,
Morton Coleman
,
Maureen E. Lane
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6522156.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6522156.v1
Purpose: This phase II study evaluated bortezomib-based secondary induction and stem cell mobilization in 38 transplant-eligible patients with myeloma who had an incomplete and stalled response to, or had relapsed after, previous immunomodulatory drug-based induction.Experimental Design: Patients received up to six 21-day cycles of bortezomib plus dexamethasone, with added liposomal doxorubicin for patients not achieving partial response or better by cycle 2 or very good partial response or better (≥VGPR) by cycle 4 (DoVeD), followed by bortezomib, high-dose cyclophosphamide, and filgrastim mobilization. Gene expression/signaling pathway analyses were conducted in purified CD34+ cells after bortezomib-based mobilization and compared against patients who received only filgrastim ± cyclophosphamide. Plasma samples were similarly analyzed for quantification of associated protein markers.Results: The response rate to DoVeD relative to the pre-DoVeD baseline was 61%, including 39% ≥VGPR. Deeper responses were achieved in 10 of 27 patients who received bortezomib-based mobilization; postmobilization response rate was 96%, including 48% ≥VGPR, relative to the pre-DoVeD baseline. Median CD34+ cell yield was 23.2 × 106 cells/kg (median of 1 apheresis session). After a median follow-up of 46.6 months, median progression-free survival was 47.1 months from DoVeD initiation; 5-year overall survival rate was 76.4%. Grade ≥3 adverse events included thrombocytopenia (13%), hand–foot syndrome (11%), peripheral neuropathy (8%), and neutropenia (5%). Bortezomib-based mobilization was associated with modulated expression of genes involved in stem cell migration.Conclusion: Bortezomib-based secondary induction and mobilization could represent an alternative strategy for elimination of tumor burden in immunomodulatory drug-resistant patients that does not impact stem cell yield. Clin Cancer Res; 19(6); 1534–46. ©2013 AACR.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.c.6522156.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361951149
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361951149Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.c.6522156.v1Digital Object Identifier
- Title
-
Data from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell MobilizationWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Rubén Niesvizky, Tomer M. Mark, Maureen Ward, David Jayabalan, Roger Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, S. Ely, Donna Skerret, Selina Chen‐Kiang, Morton Coleman, Maureen E. LaneList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.c.6522156.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.c.6522156.v1Direct OA link when available
- Concepts
-
Bortezomib, Multiple myeloma, Medicine, Filgrastim, Cyclophosphamide, Granulocyte colony-stimulating factor, Internal medicine, Autologous stem-cell transplantation, Dexamethasone, Oncology, Urology, ChemotherapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361951149 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| ids.doi | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| ids.openalex | https://openalex.org/W4361951149 |
| fwci | 0.0 |
| type | preprint |
| title | Data from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10649 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Multiple Myeloma Research and Treatments |
| topics[1].id | https://openalex.org/T12534 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9977999925613403 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Protein Degradation and Inhibitors |
| topics[2].id | https://openalex.org/T11845 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9959999918937683 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Cancer therapeutics and mechanisms |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777478702 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8407658338546753 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q419319 |
| concepts[0].display_name | Bortezomib |
| concepts[1].id | https://openalex.org/C2776364478 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6765332818031311 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[1].display_name | Multiple myeloma |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.6721593737602234 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2779171977 |
| concepts[3].level | 4 |
| concepts[3].score | 0.5109571814537048 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3151081 |
| concepts[3].display_name | Filgrastim |
| concepts[4].id | https://openalex.org/C2776755627 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5041412115097046 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q408524 |
| concepts[4].display_name | Cyclophosphamide |
| concepts[5].id | https://openalex.org/C2777767877 |
| concepts[5].level | 3 |
| concepts[5].score | 0.47649019956588745 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q419327 |
| concepts[5].display_name | Granulocyte colony-stimulating factor |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4586198031902313 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C2779050716 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4388169050216675 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q4826373 |
| concepts[7].display_name | Autologous stem-cell transplantation |
| concepts[8].id | https://openalex.org/C2780401358 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4126572906970978 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q422252 |
| concepts[8].display_name | Dexamethasone |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3562047481536865 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C126894567 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3485656976699829 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q105650 |
| concepts[10].display_name | Urology |
| concepts[11].id | https://openalex.org/C2776694085 |
| concepts[11].level | 2 |
| concepts[11].score | 0.14451804757118225 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[11].display_name | Chemotherapy |
| keywords[0].id | https://openalex.org/keywords/bortezomib |
| keywords[0].score | 0.8407658338546753 |
| keywords[0].display_name | Bortezomib |
| keywords[1].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[1].score | 0.6765332818031311 |
| keywords[1].display_name | Multiple myeloma |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.6721593737602234 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/filgrastim |
| keywords[3].score | 0.5109571814537048 |
| keywords[3].display_name | Filgrastim |
| keywords[4].id | https://openalex.org/keywords/cyclophosphamide |
| keywords[4].score | 0.5041412115097046 |
| keywords[4].display_name | Cyclophosphamide |
| keywords[5].id | https://openalex.org/keywords/granulocyte-colony-stimulating-factor |
| keywords[5].score | 0.47649019956588745 |
| keywords[5].display_name | Granulocyte colony-stimulating factor |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.4586198031902313 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/autologous-stem-cell-transplantation |
| keywords[7].score | 0.4388169050216675 |
| keywords[7].display_name | Autologous stem-cell transplantation |
| keywords[8].id | https://openalex.org/keywords/dexamethasone |
| keywords[8].score | 0.4126572906970978 |
| keywords[8].display_name | Dexamethasone |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.3562047481536865 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/urology |
| keywords[10].score | 0.3485656976699829 |
| keywords[10].display_name | Urology |
| keywords[11].id | https://openalex.org/keywords/chemotherapy |
| keywords[11].score | 0.14451804757118225 |
| keywords[11].display_name | Chemotherapy |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.c.6522156.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5077846750 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Rubén Niesvizky |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ruben Niesvizky |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5056839401 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6996-0497 |
| authorships[1].author.display_name | Tomer M. Mark |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tomer M. Mark |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5111819220 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Maureen Ward |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Maureen Ward |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5014718917 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7938-825X |
| authorships[3].author.display_name | David Jayabalan |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | David S. Jayabalan |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5113598256 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Roger Pearse |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Roger N. Pearse |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5006070488 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Megan Manco |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Megan Manco |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5058776143 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1357-724X |
| authorships[6].author.display_name | Jessica Stern |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Jessica Stern |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5024592292 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-3211-9503 |
| authorships[7].author.display_name | Paul J. Christos |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Paul J. Christos |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5025803961 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-3780-7572 |
| authorships[8].author.display_name | Lena Mathews |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Lena Mathews |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5071121646 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-6033-0747 |
| authorships[9].author.display_name | Tsiporah B. Shore |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Tsiporah B. Shore |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5028248272 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-6130-1147 |
| authorships[10].author.display_name | Faiza Zafar |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Faiza Zafar |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5068215001 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Karen Pekle |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Karen Pekle |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5111842417 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Zhaoying Xiang |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Zhaoying Xiang |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5008888803 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-1618-3617 |
| authorships[13].author.display_name | S. Ely |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Scott Ely |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5070390338 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Donna Skerret |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Donna Skerret |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5000554189 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-8549-6177 |
| authorships[15].author.display_name | Selina Chen‐Kiang |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Selina Chen-Kiang |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5082720713 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-8516-2513 |
| authorships[16].author.display_name | Morton Coleman |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Morton Coleman |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5026390249 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Maureen E. Lane |
| authorships[17].author_position | last |
| authorships[17].raw_author_name | Maureen E. Lane |
| authorships[17].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10649 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Multiple Myeloma Research and Treatments |
| related_works | https://openalex.org/W2563047534, https://openalex.org/W2527816261, https://openalex.org/W2466010828, https://openalex.org/W2169523013, https://openalex.org/W2766609975, https://openalex.org/W1992559636, https://openalex.org/W2003258318, https://openalex.org/W4301697663, https://openalex.org/W1861808521, https://openalex.org/W4250026301 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.c.6522156.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| primary_location.id | doi:10.1158/1078-0432.c.6522156.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6522156.v1 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 168 |
| abstract_inverted_index.2 | 61 |
| abstract_inverted_index.4 | 72 |
| abstract_inverted_index.a | 172 |
| abstract_inverted_index.10 | 136 |
| abstract_inverted_index.27 | 138 |
| abstract_inverted_index.38 | 14 |
| abstract_inverted_index.II | 3 |
| abstract_inverted_index.an | 21, 230 |
| abstract_inverted_index.by | 59, 70, 75 |
| abstract_inverted_index.in | 13, 88, 135, 219, 238 |
| abstract_inverted_index.of | 43, 112, 137, 167, 175, 216, 235 |
| abstract_inverted_index.or | 27, 57, 62, 67 |
| abstract_inverted_index.to | 39, 119, 122, 153 |
| abstract_inverted_index.up | 38 |
| abstract_inverted_index.± | 103 |
| abstract_inverted_index.× | 163 |
| abstract_inverted_index.39% | 129 |
| abstract_inverted_index.48% | 150 |
| abstract_inverted_index.The | 116 |
| abstract_inverted_index.and | 9, 23, 79, 95, 206, 226 |
| abstract_inverted_index.for | 51, 110, 233 |
| abstract_inverted_index.had | 20, 28 |
| abstract_inverted_index.not | 53, 244 |
| abstract_inverted_index.six | 40 |
| abstract_inverted_index.the | 123, 154 |
| abstract_inverted_index.to, | 26 |
| abstract_inverted_index.was | 126, 147, 161, 181, 191, 211 |
| abstract_inverted_index.who | 19, 99, 140 |
| abstract_inverted_index.23.2 | 162 |
| abstract_inverted_index.46.6 | 176 |
| abstract_inverted_index.47.1 | 182 |
| abstract_inverted_index.61%, | 127 |
| abstract_inverted_index.96%, | 148 |
| abstract_inverted_index.Gene | 82 |
| abstract_inverted_index.Res; | 251 |
| abstract_inverted_index.This | 1 |
| abstract_inverted_index.cell | 11, 159, 221, 247 |
| abstract_inverted_index.does | 243 |
| abstract_inverted_index.from | 184 |
| abstract_inverted_index.good | 64 |
| abstract_inverted_index.only | 101 |
| abstract_inverted_index.plus | 45 |
| abstract_inverted_index.rate | 118, 146, 190 |
| abstract_inverted_index.stem | 10, 220, 246 |
| abstract_inverted_index.that | 242 |
| abstract_inverted_index.very | 63 |
| abstract_inverted_index.were | 86, 107, 133 |
| abstract_inverted_index.with | 17, 47, 213 |
| abstract_inverted_index.≥3 | 194 |
| abstract_inverted_index.(5%). | 208 |
| abstract_inverted_index.(8%), | 205 |
| abstract_inverted_index.After | 171 |
| abstract_inverted_index.CD34+ | 90, 158 |
| abstract_inverted_index.DoVeD | 120, 185 |
| abstract_inverted_index.Grade | 193 |
| abstract_inverted_index.added | 48 |
| abstract_inverted_index.after | 92 |
| abstract_inverted_index.cells | 91 |
| abstract_inverted_index.could | 228 |
| abstract_inverted_index.cycle | 60, 71 |
| abstract_inverted_index.genes | 217 |
| abstract_inverted_index.phase | 2 |
| abstract_inverted_index.study | 4 |
| abstract_inverted_index.tumor | 236 |
| abstract_inverted_index.yield | 160 |
| abstract_inverted_index.(11%), | 202 |
| abstract_inverted_index.(13%), | 199 |
| abstract_inverted_index.19(6); | 252 |
| abstract_inverted_index.21-day | 41 |
| abstract_inverted_index.5-year | 187 |
| abstract_inverted_index.76.4%. | 192 |
| abstract_inverted_index.Cancer | 250 |
| abstract_inverted_index.Deeper | 131 |
| abstract_inverted_index.Median | 157 |
| abstract_inverted_index.Plasma | 105 |
| abstract_inverted_index.after, | 30 |
| abstract_inverted_index.better | 58, 68 |
| abstract_inverted_index.burden | 237 |
| abstract_inverted_index.cycles | 42 |
| abstract_inverted_index.events | 196 |
| abstract_inverted_index.impact | 245 |
| abstract_inverted_index.median | 173, 178 |
| abstract_inverted_index.months | 183 |
| abstract_inverted_index.yield. | 248 |
| abstract_inverted_index.©2013 | 254 |
| abstract_inverted_index.(median | 166 |
| abstract_inverted_index.adverse | 195 |
| abstract_inverted_index.against | 97 |
| abstract_inverted_index.months, | 177 |
| abstract_inverted_index.myeloma | 18 |
| abstract_inverted_index.overall | 188 |
| abstract_inverted_index.partial | 55, 65 |
| abstract_inverted_index.pathway | 84 |
| abstract_inverted_index.protein | 114 |
| abstract_inverted_index.samples | 106 |
| abstract_inverted_index.stalled | 24 |
| abstract_inverted_index.(DoVeD), | 73 |
| abstract_inverted_index.Patients | 36 |
| abstract_inverted_index.achieved | 134 |
| abstract_inverted_index.analyses | 85 |
| abstract_inverted_index.analyzed | 109 |
| abstract_inverted_index.baseline | 125 |
| abstract_inverted_index.cells/kg | 165 |
| abstract_inverted_index.compared | 96 |
| abstract_inverted_index.followed | 74 |
| abstract_inverted_index.included | 197 |
| abstract_inverted_index.involved | 218 |
| abstract_inverted_index.patients | 16, 52, 98, 139, 241 |
| abstract_inverted_index.previous | 31 |
| abstract_inverted_index.purified | 89 |
| abstract_inverted_index.received | 37, 100, 141 |
| abstract_inverted_index.relapsed | 29 |
| abstract_inverted_index.relative | 121, 152 |
| abstract_inverted_index.response | 25, 56, 66, 117, 145 |
| abstract_inverted_index.strategy | 232 |
| abstract_inverted_index.survival | 180, 189 |
| abstract_inverted_index.syndrome | 201 |
| abstract_inverted_index.≥VGPR, | 151 |
| abstract_inverted_index.≥VGPR. | 130 |
| abstract_inverted_index.(≥VGPR) | 69 |
| abstract_inverted_index.achieving | 54 |
| abstract_inverted_index.apheresis | 169 |
| abstract_inverted_index.baseline. | 156 |
| abstract_inverted_index.conducted | 87 |
| abstract_inverted_index.evaluated | 5 |
| abstract_inverted_index.follow-up | 174 |
| abstract_inverted_index.high-dose | 77 |
| abstract_inverted_index.including | 128, 149 |
| abstract_inverted_index.induction | 8, 225 |
| abstract_inverted_index.liposomal | 49 |
| abstract_inverted_index.modulated | 214 |
| abstract_inverted_index.pre-DoVeD | 124, 155 |
| abstract_inverted_index.represent | 229 |
| abstract_inverted_index.responses | 132 |
| abstract_inverted_index.secondary | 7, 224 |
| abstract_inverted_index.session). | 170 |
| abstract_inverted_index.similarly | 108 |
| abstract_inverted_index.1534–46. | 253 |
| abstract_inverted_index.associated | 113, 212 |
| abstract_inverted_index.bortezomib | 44 |
| abstract_inverted_index.drug-based | 33 |
| abstract_inverted_index.expression | 215 |
| abstract_inverted_index.filgrastim | 80, 102 |
| abstract_inverted_index.incomplete | 22 |
| abstract_inverted_index.neuropathy | 204 |
| abstract_inverted_index.peripheral | 203 |
| abstract_inverted_index.alternative | 231 |
| abstract_inverted_index.bortezomib, | 76 |
| abstract_inverted_index.doxorubicin | 50 |
| abstract_inverted_index.elimination | 234 |
| abstract_inverted_index.hand–foot | 200 |
| abstract_inverted_index.initiation; | 186 |
| abstract_inverted_index.neutropenia | 207 |
| abstract_inverted_index.mobilization | 12, 94, 210, 227 |
| abstract_inverted_index.<i>Clin | 249 |
| abstract_inverted_index.mobilization. | 81 |
| abstract_inverted_index.mobilization; | 143 |
| abstract_inverted_index.dexamethasone, | 46 |
| abstract_inverted_index.drug-resistant | 240 |
| abstract_inverted_index.quantification | 111 |
| abstract_inverted_index.Bortezomib-based | 209, 223 |
| abstract_inverted_index.bortezomib-based | 6, 93, 142 |
| abstract_inverted_index.immunomodulatory | 32, 239 |
| abstract_inverted_index.postmobilization | 144 |
| abstract_inverted_index.progression-free | 179 |
| abstract_inverted_index.thrombocytopenia | 198 |
| abstract_inverted_index.Design:</b> | 35 |
| abstract_inverted_index.cyclophosphamide, | 78 |
| abstract_inverted_index.cyclophosphamide. | 104 |
| abstract_inverted_index.transplant-eligible | 15 |
| abstract_inverted_index.expression/signaling | 83 |
| abstract_inverted_index.10<sup>6</sup> | 164 |
| abstract_inverted_index.AACR</i>.</p></div> | 255 |
| abstract_inverted_index.induction.</p><p><b>Experimental | 34 |
| abstract_inverted_index.markers.</p><p><b>Results:</b> | 115 |
| abstract_inverted_index.<div>Abstract<p><b>Purpose:</b> | 0 |
| abstract_inverted_index.migration.</p><p><b>Conclusion:</b> | 222 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 18 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.41999998688697815 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.1182366 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |